Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Files An 8-K Results of Operations and Financial Condition


Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On March12, 2018, Merrimack Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December31, 2017.The full text of the press release issued in connection with the announcement is furnished as Exhibit99.1 to this Current Report on Form8-K.

The information in this Form8-K (including Exhibit99.1) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02. Financial Statements and Exhibits.

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

99.1 Press release issued by the Registrant on March12, 2018

EX-99.1 2 d463549dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Merrimack Provides Business Update and Reports 2017 Financial Results – Strengthened the randomized Phase 2 SHERLOC study evaluating MM-121 in non-small cell lung cancer by expanding enrollment from 80 to 100 patients – – Dosed the first patient in randomized Phase 2 SHERBOC study evaluating MM-121 in metastatic breast cancer – – Announced the formation of a new Scientific Advisory Board with extensive expertise in precision oncology – – Expects three clinical readouts in 2018,…
To view the full exhibit click here

About Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

An ad to help with our costs